HMGB1 and leiomyosarcoma: In conclusion, despite encouraging trends, it would be premature to interpret increased HMGB1 as an unequivocal sign of good prognosis in patients with advanced leiomyosarcoma treated with doxorubicin, dacarbazine and nivolumab.